复星医药：注射用奈达铂的药品注册申请获国家药监局受理

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of injectable Nedaplatin, which is a self-developed chemical drug intended for various cancers [1] Group 1 - The drug is designed for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, testicular tumors, ovarian cancer, and cervical cancer [1] - As of July 2025, the total R&D investment for this drug is approximately RMB 5.66 million (unaudited) [1]